Exousia Bio (LMMY) Liabilities and Shareholders Equity (2022 - 2025)

Exousia Bio has disclosed Liabilities and Shareholders Equity across 4 years of filings, most recently posting $22.1 million for Q4 2025.

• Liabilities and Shareholders Equity for Q4 2025 came in at $22.1 million, up 88620.81% year-over-year; the trailing twelve-month figure through Nov 2025 was $22.1 million (up 20468.31% YoY), and the FY2024 annual result was $27453.0, down 25.89% from the prior year.
• Liabilities and Shareholders Equity came in at $22.1 million for Q4 2025 at Exousia Bio, up from $24854.0 in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $22.1 million in Q4 2025 to a low of $24854.0 in Q4 2024.
• The 4-year median for Liabilities and Shareholders Equity is $27705.5 (2024), against an average of $2.2 million.
• Across the five-year window, Liabilities and Shareholders Equity sank 31.39% in 2023 and surged 88620.81% in 2025, its largest moves.
• Exousia Bio's Liabilities and Shareholders Equity stood at $53996.0 in 2022, then plunged by 50.47% to $26742.0 in 2023, then declined by 7.06% to $24854.0 in 2024, then soared by 88620.81% to $22.1 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $22.1 million (Q4 2025), $24854.0 (Q4 2024), and $27958.0 (Q3 2024), per Business Quant data.